A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Cardiovascular Center Bethanien · German Breast group · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
689
total citations
- FWCI
- 27.28
- Percentile
- 100%
- References
- 22
Citations per year
Authors
23- SLS. LoiblCorresponding
Cardiovascular Center Bethanien, German Breast group
- MUMichael Untch
Helios Hospital Berlin-Buch
- NBNicole Burchardi
German Breast group
- JHJens Huober
Universitäts Frauenklinik
- BVBruno V. Sinn
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin
Topics & keywords
Topics
Keywords
- Medicine
- Taxane
- Anthracycline
- Triple-negative breast cancer
- Oncology
- Breast cancer
- Neoadjuvant therapy
- Durvalumab
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.